RCT: Adalimumab introduction vs. methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis.

Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study – The Lancet Rheumatology (link to abstract – $ for full-text)

Commentary: Adalimumab Addition vs. Methotrexate Escalation in Psoriatic Arthritis – RheumNow

Commentary on Twitter

NEW RESEARCH—A randomised, open-label, phase 4 trial supports the addition of #adalimumab over escalating #methotrexate in patients with #PsoriaticArthritis not reaching minimal disease activity after an initial methotrexate course https://t.co/LUpzAw71lD #LancetRheumatology pic.twitter.com/ouqTyITlxC

— The Lancet Rheumatology (@TheLancetRheum) February 28, 2022